APA

Conroy T., Cappelaere P., Fabbro M., Fauser A. A., Splinter T. A., Spielmann M., Schneider M., Chevallier B., Goupil A. & Chauvergne J. (19940428). Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. : American journal of clinical oncology.

Chicago

Conroy T, Cappelaere P, Fabbro M, Fauser A A, Splinter T A, Spielmann M, Schneider M, Chevallier B, Goupil A and Chauvergne J. 19940428. Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. : American journal of clinical oncology.

Harvard

Conroy T., Cappelaere P., Fabbro M., Fauser A. A., Splinter T. A., Spielmann M., Schneider M., Chevallier B., Goupil A. and Chauvergne J. (19940428). Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. : American journal of clinical oncology.

MLA

Conroy T, Cappelaere P, Fabbro M, Fauser A A, Splinter T A, Spielmann M, Schneider M, Chevallier B, Goupil A and Chauvergne J. Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. : American journal of clinical oncology. 19940428.